Opportunistic infections are infections that occur more frequently in people with advanced HIV disease, including tuberculosis, cryptococcal meningitis, pneumonia and toxoplasmosis.

Opportunistic infections: latest news

Opportunistic infections resources

  • Tuberculosis

    Tuberculosis (TB) is an infection that usually affects the lungs.It can be very serious, particularly for people living with HIV who have a low CD4 count.TB can...

    From: Factsheets

    Information level Level 2
  • Cancer and HIV

    Rates of some, but not all, cancers are higher in people living with HIV than other people.For many cancers, treatment works just as well for...

    From: Factsheets

    Information level Level 2
  • Herpes

    Herpes is transmitted by contact with skin where the herpes simplex virus is present. It causes painful blisters on the genital and surrounding areas.Antiviral treatments...

    From: Factsheets

    Information level Level 2
  • Kaposi’s sarcoma and HIV

    Kaposi’s sarcoma remains one of the most common cancers in people living with HIV.HIV treatment protects against Kaposi’s sarcoma and slows down disease progression.People with...

    From: Factsheets

    Information level Level 2
  • Candidiasis (thrush)

    Candidiasis (thrush) is a common yeast infection, treated with anti-fungal drugs.Mild candidiasis in the mouth is relatively common in people with HIV.Good oral hygiene can reduce the...

    From: Factsheets

    Information level Level 2
  • Non-Hodgkin lymphoma and HIV

    Non-Hodgkin lymphoma (NHL) is a cancer affecting the immune system. People with weakened immune systems, including people with HIV, are at increased risk of developing NHL. Most people with...

    From: Factsheets

    Information level Level 2

Opportunistic infections features

Opportunistic infections in your own words

Opportunistic infections news from aidsmap

More news

Opportunistic infections news selected from other sources

  • A Mysterious Infection, Spanning the Globe in a Climate of Secrecy

    The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in India, Pakistan and South Africa.

    08 April 2019 | New York Times
  • Study: AIDS-immunocompromised populations see more antibiotic-resistant infections

    Populations with a high prevalence of AIDS-immunocompromised people are more likely to see the emergence of antibiotic-resistant bacterial infections, according to a study coauthored by researchers at the University of Tennessee, Knoxville, and published in PLOS One.

    27 March 2019 | Eurekalert Inf Dis
  • Back to the future with CD4 testing: Improving HIV care in low- and middle-income countries

    A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.

    16 January 2019 | Science Daily
  • HIV-Positive Patients at Higher Risk of Late Mortality Following Cryptococcal Infection

    New research being presented in a Poster Abstract Session at ID Week 2018, suggests that patients living with HIV have high mortality following cryptococcal infection which persists beyond initial hospitalization. As such, the investigators stress the need to identify patients who are at increased risk of mortality in order to improve patient outcomes.

    04 October 2018 | Contagionlive.com
  • Uganda: No More Septrin for Aids Patients - Government

    People living with HIV/Aids in Uganda (PLWHA) will stop taking Septrin as a complementary drug that fights opportunistic infections such as malaria, diarrhoea and pneumonia, according to the new Health ministry guidelines.

    04 September 2018 | AllAfrica
  • Price cut on medicine will help preserve the health of more people living with HIV

    Unitaid and Indian drug manufacturer Cipla Ltd. struck a landmark agreement today that will lower the price of the first combination therapy (containing co-trimoxazole, isoniazid and vitamin B6) that prevents opportunistic infections in people living with HIV.

    11 June 2018 | UNITAID
  • Raltegravir-Intensified ART: More Rapid Declines in HIV Viral Load But No Impact On IRIS

    At the 25th Conference on Retroviruses and Opportunistic Infections (CROI) Diana Gibb, MD, professor of epidemiology, program leader of the Pediatric Program of trials and cohorts at the Medical Research Council Clinical Trials Unit at UCL, London, shared results from a REALITY trial (ISRCTN43622374) which explored the impact of raltegravir intensification of first-line antiretroviral therapy (ART) on immune reconstitution inflammatory syndrome (IRIS).

    13 March 2018 | Contagion Live
  • Deadly cryptococcal fungi found in public spaces in South Africa

    After tuberculosis, cryptococcal meningitis is the leading cause of death in HIV/AIDS patients in Sub-Saharan Africa.

    08 December 2017 | Science Daily
  • HIV: MSF concerned by high numbers of AIDS deaths in sub-Saharan Africa

    Global attention is needed to prevent and treat AIDS in antiretroviral era, with 50 per cent of hospital admissions in MSF hospitals already on treatment and showing signs of clinical failure.

    25 July 2017 | Médecins Sans Frontières (MSF) International
  • Pneumococcal infections decrease in patients with suppressed HIV

    Pneumococcal infections among patients with virologically suppressed HIV decreased significantly in recent years, according to data from a retrospective, case-controlled study.

    08 November 2016 | Healio
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.